UB-312 as an Investigational Immunotherapy Targeting α-Synuclein in Parkinson’s Disease

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Alpha-synuclein (αSyn) is a neuronal protein localized at presynaptic terminals and involved in the regulation of neurotransmitter release. Under normal physiological conditions, αSyn contributes to synaptic homeostasis. However, pathological misfolding and aggregation of αSyn result in the development of synucleinopathies, a group of progressive neurodegenerative disorders. Among these, Parkinson’s disease (PD) is the most prevalent, ranking as the second most common neurodegenerative condition globally. Despite extensive research, no disease-modifying therapies for PD are currently available.

Evidence indicates that accumulation of αSyn aggregates is central to PD progression. Strategies aimed at preventing or reducing αSyn aggregation may therefore offer therapeutic benefit. One of the principal barriers to such approaches is the restrictive nature of the blood–brain barrier (BBB), which limits the entry of circulating proteins and antibodies into the central nervous system.

Novel Immunotherapeutic Approach

Advances in immunology and molecular design have enabled the development of vaccine-based strategies capable of targeting αSyn within the brain. UB-312, a fully synthetic peptide conjugated to a T-helper epitope, has been engineered to stimulate the immune system to generate antibodies against pathological αSyn assemblies. Preclinical data and early-phase clinical studies suggest UB-312 can induce antibodies that recognize both oligomeric and fibrillar forms of αSyn, potentially interrupting disease progression.

Mechanism of Action

UB-312 targets a defined 12-amino acid sequence in the C-terminal region of αSyn. Antibodies generated following vaccination recognize and bind multiple conformational states of αSyn, including oligomers and fibrils. This broad recognition capacity may prevent new fibril formation and promote clearance of existing toxic aggregates. Experimental studies in animal models have demonstrated antibody penetration into the brain, engagement with pathological αSyn, and subsequent reduction of αSyn burden without inducing harmful T-cell infiltration.

Preclinical and Clinical Findings

In preclinical models, UB-312 immunization has been associated with reduced αSyn oligomer levels, improved motor function, and enhanced local immune surveillance. Importantly, these effects were achieved without provoking excessive neuroinflammation, a common limitation of previous immunotherapeutic approaches.

A first-in-human clinical study enrolled 23 participants who received three escalating doses of UB-312. The vaccine was well tolerated, with only mild and transient adverse events reported, such as headache, fatigue, localized injection-site reactions, nasopharyngitis, and lumbar puncture discomfort. Cerebrospinal fluid and serum analyses confirmed dose-dependent induction of anti-αSyn antibodies. These antibodies demonstrated reactivity against pathogenic αSyn aggregates derived from post-mortem PD brain tissue.

Safety Considerations

One of the major advantages of UB-312 lies in its design to avoid excessive pro-inflammatory responses. While immunotherapies can trigger uncontrolled inflammation and subsequent neuronal apoptosis, UB-312 preferentially elicits a humoral immune response. This mechanism reduces the risk of neurotoxicity while still enabling efficient clearance of pathological αSyn assemblies.

Therapeutic Potential Beyond PD

Given the central role of αSyn aggregation across multiple neurodegenerative disorders, UB-312 may have therapeutic implications beyond Parkinson’s disease. Other synucleinopathies, including dementia with Lewy bodies and multiple system atrophy, could potentially benefit from similar antibody-mediated approaches.

Conclusion

UB-312 represents a promising investigational vaccine for the treatment of synucleinopathies. Its capacity to generate antibodies that cross the BBB, recognize toxic αSyn species, and reduce aggregation while maintaining an acceptable safety profile underscores its potential clinical utility. Although early findings are encouraging, further clinical evaluation in patients with Parkinson’s disease is required to establish its efficacy, optimal dosing strategy, and long-term safety.

UB-312 is the first active immunotherapy to demonstrate clinically relevant antibody induction against αSyn in humans, marking a significant step toward disease-modifying therapy in PD.

REFERENCES

1. Nimmo JT, Smith H, Wang CY, Teeling JL, Nicoll JA, Verma A, Savistchenko J, Melki R, Carare RO. Immunization with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol. 2022;143(1):55-73.
2. Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, Dodart JC, et al. A randomized first-in-human study with UB-312, a UBITh α-synuclein peptide vaccine. Mov Disord. 2022;37(7):1416-24.
3. ClinicalTrials.gov. Phase 1 study of UB-312 in healthy participants and Parkinson’s disease patients: safety, tolerability, and immunogenicity of UBITh PD immunotherapeutic vaccine (UB-312). Identifier: NCT04075318.
4. ClinicalTrials.gov. Phase 1b clinical trial of UB-312 in patients with synucleinopathies (Parkinson disease and multiple system atrophy). Identifier: NCT05634876.
5. Millar Vernetti P, Mirski D, Dodart JC, Wood A, Yu HJ, Boyd J, Kundu P, Setton R, Silbersweig D, Stern E, Lucero C, Gerrol S, Kaufmann H, Martinez J. A phase 1b randomized, placebo-controlled, delayed-start trial of UB-312 in synucleinopathies. Mov Disord Congress Abstracts. 2024; Abstract No. 639.
6. UB-312 update on immune-based α-synuclein trials in Parkinson’s disease. J Neurol. 2024;271(5):1234-1245.
7. Nimmo JT, Verma A, Dodart JC, Wang CY, Savistchenko J, Melki R, Carare RO, et al. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimers Res Ther. 2020;12:121.
8. Vaxxinity Inc, Dodart JC, Yu HJ, Kaufmann H, Martinez J, et al. UB-312 reduces α-synuclein in Parkinson’s disease in Phase 1 trial: target engagement data from Part B. Neurology Live/ADPD Conference Abstracts. 2024.